Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer
Heron Therapeutics, Inc. (HRTX)
Last heron therapeutics, inc. earnings: 3/2 07:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
herontherapeutics.gcs-web.com/investor-home
Company Research
Source: PR Newswire
Impact Snapshot
Event Time:
HRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HRTX alerts
High impacting Heron Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
HRTX
News
- Heron Therapeutics, Inc. (NASDAQ: HRTX) was downgraded by analysts at StockNews.com from a "buy" rating to a "hold" rating.MarketBeat
- Heron Therapeutics, Inc. (NASDAQ: HRTX) was upgraded by analysts at StockNews.com from a "hold" rating to a "buy" rating.MarketBeat
- Heron Therapeutics, Inc. (NASDAQ: HRTX) had its price target lowered by analysts at Needham & Company LLC from $5.00 to $4.00. They now have a "buy" rating on the stock.MarketBeat
- Heron Therapeutics Inc (HRTX) Q3 2024 Earnings Call Highlights: Strategic Initiatives Drive ... [Yahoo! Finance]Yahoo! Finance
- Heron Therapeutics (HRTX) Q3 Earnings: How Key Metrics Compare to Wall Street Estimates [Yahoo! Finance]Yahoo! Finance
HRTX
Earnings
- 11/12/24 - In-Line
HRTX
Sec Filings
- 11/12/24 - Form SC
- 11/12/24 - Form 10-Q
- 11/12/24 - Form 8-K
- HRTX's page on the SEC website